Cantourage Plans Questionnaire Route for Telecan Cannabis Care

Cantourage Group SE (HIGH.DE ) announced on November 9, 2026 that its Telecan telemedicine platform will offer a questionnaire-based route for physicians to review treatment requests, supplementing the existing video-consultation service. The planned option is intended to make access to physician-led care more straightforward and flexible for patients with a corresponding medical need, including those seeking medical cannabis treatment where appropriate.

The additional access route is designed for both existing registered patients and new patients seeking an assessment of their medical treatment needs. Its stated focus is appropriate care tailored to individual needs, not use of the platform itself. No separate availability or launch date was disclosed, making this an announced development rather than a confirmed service start.

Physician Review and Prescribing Safeguards

Under the planned pathway, patients initially submit medical information through a structured digital questionnaire. A licensed physician can ask follow-up questions or arrange an additional consultation before independently deciding whether a prescription is appropriate. The company says the offering is structured in accordance with applicable medical and legal requirements.

Paul Thies, managing director of Apsat GmbH (Telecan), said: “This additional digital pathway expressly does not constitute automated prescribing. Every treatment case is reviewed individually by a licensed physician, who arranges direct physician-patient contact whenever medically or legally necessary.”

Thies said the development is intended to make qualified medical assessments easier to access by making meaningful use of digital opportunities, while maintaining high standards of medical quality and regulatory compliance. The platform was also developed to respond flexibly to future legislative changes. Cantourage regards the additional route as a complement to its existing services and a form of physician contact already established in digital healthcare.

Strategic Role and Revenue Distinction

Telecan is an important element of Cantourage’s positioning in the German medical cannabis market and supports access to care provided under physicians’ responsibility. Cantourage says its product revenue comes from distributing medical cannabis products to pharmacies, rather than from the telemedicine platform itself, and that the expansion may indirectly create additional commercial opportunities in that pharmacy business.

Philip Schetter, CEO of Cantourage Group SE, linked the development to the company’s longer-term outlook: “We believe that the patient-focused development of digital healthcare services can also provide positive momentum for our business over the long term.”

The planned pathway separates broader access to an assessment from the prescribing decision itself. Its significance for patients rests on adding flexibility without replacing individual physician judgment, while its significance for Cantourage rests on indirect pharmacy opportunities rather than a new telemedicine revenue stream.